Kite cues up first EMA okay for mantle cell lymphoma CAR-TGilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for Share XKite cues up first EMA okay for mantle cell lymphoma CAR-Thttps://pharmaphorum.com/news/kite-cues-up-first-ema-okay-for-mantle-cell-lymphoma-car-t/
Gilead’s Kite gains some height after second CAR-T approval in USGilead’s $11.9 billion purchase of Kite Pharma in 2017 didn’t follow the script, with two big write-downs in Share XGilead’s Kite gains some height after second CAR-T approval in UShttps://pharmaphorum.com/news/gileads-kite-gains-some-height-after-second-car-t-approval-in-us/
Gilead closes in on second CAR-T approval in USThe FDA is due to decide by 10 August whether it will approve a second CAR-T therapy from Share XGilead closes in on second CAR-T approval in UShttps://pharmaphorum.com/news/gilead-closes-in-on-second-car-t-approval-in-us/
EMA starts review of second CAR-T from Gilead’s Kite unitThe EU regulator has started its review of a second CAR-T from Gilead Sciences’ Kite Pharma subsidiary, setting Share XEMA starts review of second CAR-T from Gilead’s Kite unithttps://pharmaphorum.com/news/ema-starts-review-of-second-car-t-from-gileads-kite-unit/
Gilead to file new CAR-T, setting up potential mid-2020 launchGilead’s Kite unit plans to file its latest CAR-T therapy on the basis of a new study showing Share XGilead to file new CAR-T, setting up potential mid-2020 launchhttps://pharmaphorum.com/news/gilead-to-file-new-car-t/
Calquence approval another win for AstraZeneca in oncologyAstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next Share XCalquence approval another win for AstraZeneca in oncologyhttps://pharmaphorum.com/news/calquence-approval-another-win-astrazeneca-oncology/
Janssen’s Imbruvica runs into trouble with NICE in mantle cell lymphomaNICE suggests interim CDF funding while further data is gathered. Share XJanssen’s Imbruvica runs into trouble with NICE in mantle cell lymphomahttps://pharmaphorum.com/news/imbruvica-mantle-cell-lymphoma/